CN107469087A - 用于治疗精神病的制剂 - Google Patents
用于治疗精神病的制剂 Download PDFInfo
- Publication number
- CN107469087A CN107469087A CN201710809408.7A CN201710809408A CN107469087A CN 107469087 A CN107469087 A CN 107469087A CN 201710809408 A CN201710809408 A CN 201710809408A CN 107469087 A CN107469087 A CN 107469087A
- Authority
- CN
- China
- Prior art keywords
- milligrams
- milligram
- acid
- preparation
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000561 anti-psychotic effect Effects 0.000 title claims abstract description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 16
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003120 clonazepam Drugs 0.000 claims abstract description 11
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 9
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims abstract description 9
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims abstract description 9
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 claims abstract description 9
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 claims abstract description 9
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 9
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960005017 olanzapine Drugs 0.000 claims abstract description 9
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001534 risperidone Drugs 0.000 claims abstract description 9
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004334 sorbic acid Substances 0.000 claims abstract description 9
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 9
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 9
- 239000001530 fumaric acid Substances 0.000 claims abstract description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 239000012190 activator Substances 0.000 claims abstract description 6
- 229960005137 succinic acid Drugs 0.000 claims abstract description 6
- 239000000181 nicotinic agonist Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 206010026749 Mania Diseases 0.000 abstract description 4
- 230000003340 mental effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于治疗精神病的制剂，由氯硝西泮1‑2毫克、奥氮平1‑2毫克、里斯普里酮1‑2毫克、大麻环萜酚0.5‑1毫克、琥珀酸0.5‑1毫克、富马酸0.5‑1毫克、苯甲酸0.5‑1毫克、山梨酸0.5‑1毫克、甘氨酸转运蛋白抑制剂0.25‑0.5毫克、α7烟碱激动剂0.25‑0.5毫克组成；本发明的优点在于：尤其适用于狂躁不安、哭笑无常、毁物伤人、语无伦次、不寐少食、多疑善惑、气郁狂热等症状的精神病患者，起效快，服药周期短。
Description
技术领域
本发明涉及一种药物，具体地说是一种用于治疗精神病的制剂，属于药物领域。
背景技术
精神方面的疾病表现症状，有大脑功能紊乱导致的精神分裂症，各种复杂的社会、心理因素及工作各个方面的压力而引起的人体内脏功能失调，导致失眠多梦、多疑焦虑、忧郁症、劳思过度、精神恍惚、幻觉妄想、兴奋躁动、苦笑无常、语言错乱、性格孤僻、情绪反常、受惊吓等。精神方面的疾病，大多是由于大脑功能活动发生一紊乱，出现精神障碍，或者是受各种复杂的社会环境、心理素质及工作压力等而引起的人体内脏功能失调，以及遗传基因，也能导致精神方面的疾病。名称为“一种治疗精神病的黑白制剂组方”申请号为“200610072884.7”的中国发明专利公开了一种治疗精神病的黑白制剂组方，其黑白制剂为两个单独的组份,分别由抗精神病药及氯硝西泮(氯硝安定)组成。黑制剂晚服,白制剂昼服。分别将黑白制剂各几种原料药进行单独的工艺处理。黑制剂可达到目前各种抗精神病药的疗效,并有抗焦虑、镇静安眠作用,白制剂可配合黑制剂达到抗精神病药的疗效,并有抗焦虑和抗抑郁作用。然而，该产品起效满，服药周期长，治愈率低，而且具有副作用。
发明内容
为了解决上述问题，本发明设计了一种用于治疗精神病的制剂，尤其适用于狂躁不安、哭笑无常、毁物伤人、语无伦次、不寐少食、多疑善惑、气郁狂热等症状的精神病患者，起效快，服药周期短。
本发明的技术方案为：
用于治疗精神病的制剂，由以下组分组成：
氯硝西泮1-2毫克、奥氮平1-2毫克、里斯普里酮1-2毫克、大麻环萜酚0.5-1毫克、琥珀酸0.5-1毫克、富马酸0.5-1毫克、苯甲酸0.5-1毫克、山梨酸0.5-1毫克、甘氨酸转运蛋白抑制剂0.25-0.5毫克、α7烟碱激动剂0.25-0.5毫克。
其中，氯硝西泮、奥氮平、里斯普里酮作为抗精神病药物，能够适用于狂躁不安、哭笑无常、毁物伤人、语无伦次、不寐少食、多疑善惑、气郁狂热等症状；大麻环萜酚、琥珀酸、富马酸、苯甲酸、山梨酸、甘氨酸转运蛋白抑制剂、α7烟碱激动剂能够增加神经药物药方的疗效；
优选地，氯硝西泮1.5毫克、奥氮平1.5毫克、里斯普里酮1.5毫克、大麻环萜酚1毫克、琥珀酸0.5毫克、富马酸0.5毫克、苯甲酸0.5毫克、山梨酸0.5毫克、甘氨酸转运蛋白抑制剂0.25毫克、α7烟碱激动剂0.25毫克。
通过采用本发明上述组分，不但能够预防和治疗精神病及精神障碍，二期还能够减少或消除药物的不良副作用，同时，提高药物疗效，起效快，服药周期短。
本发明的优点在于：尤其适用于狂躁不安、哭笑无常、毁物伤人、语无伦次、不寐少食、多疑善惑、气郁狂热等症状的精神病患者，起效快，服药周期短。
下面结合具体实施例对本发明作进一步说明。
具体实施方式
以下对本发明的优选实施例进行说明，应当理解，此处所描述的优选实施例仅用于说明和解释本发明，并不用于限定本发明。
实施例1
用于治疗精神病的制剂，由以下组分组成：
氯硝西泮1毫克、奥氮平1毫克、里斯普里酮1毫克、大麻环萜酚0.5毫克、琥珀酸0.5毫克、富马酸0.5毫克、苯甲酸0.5毫克、山梨酸0.5毫克、甘氨酸转运蛋白抑制剂0.25毫克、α7烟碱激动剂0.25毫克。
实施例2
用于治疗精神病的制剂，由以下组分组成：
氯硝西泮2毫克、奥氮平2毫克、里斯普里酮2毫克、大麻环萜酚1毫克、琥珀酸1毫克、富马酸1毫克、苯甲酸1毫克、山梨酸1毫克、甘氨酸转运蛋白抑制剂0.5毫克、α7烟碱激动剂0.5毫克。
实施例3
用于治疗精神病的制剂，由以下组分组成：
氯硝西泮1.5毫克、奥氮平1.5毫克、里斯普里酮1.5毫克、大麻环萜酚1毫克、琥珀酸0.5毫克、富马酸0.5毫克、苯甲酸0.5毫克、山梨酸0.5毫克、甘氨酸转运蛋白抑制剂0.25毫克、α7烟碱激动剂0.25毫克。
通过采用本发明上述组分，不但能够预防和治疗精神病及精神障碍，二期还能够减少或消除药物的不良副作用，同时，提高药物疗效，起效快，服药周期短。
经临床患者使用100例，其有效率达100%，治愈率达97%，服药后30分钟见效，起效快，服药周期短。
Claims (2)
1.用于治疗精神病的制剂，其特征在于，由以下组分组成：
氯硝西泮1-2毫克、奥氮平1-2毫克、里斯普里酮1-2毫克、大麻环萜酚0.5-1毫克、琥珀酸0.5-1毫克、富马酸0.5-1毫克、苯甲酸0.5-1毫克、山梨酸0.5-1毫克、甘氨酸转运蛋白抑制剂0.25-0.5毫克、α7烟碱激动剂0.25-0.5毫克。
2.根据权利要求1所述的用于治疗精神病的制剂，其特征在于，由以下组分组成：
氯硝西泮1.5毫克、奥氮平1.5毫克、里斯普里酮1.5毫克、大麻环萜酚1毫克、琥珀酸0.5毫克、富马酸0.5毫克、苯甲酸0.5毫克、山梨酸0.5毫克、甘氨酸转运蛋白抑制剂0.25毫克、α7烟碱激动剂0.25毫克。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710809408.7A CN107469087A (zh) | 2017-09-10 | 2017-09-10 | 用于治疗精神病的制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710809408.7A CN107469087A (zh) | 2017-09-10 | 2017-09-10 | 用于治疗精神病的制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107469087A true CN107469087A (zh) | 2017-12-15 |
Family
ID=60584746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710809408.7A Pending CN107469087A (zh) | 2017-09-10 | 2017-09-10 | 用于治疗精神病的制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107469087A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1791430A (zh) * | 2003-05-16 | 2006-06-21 | 辉瑞产品公司 | 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合 |
| CN101939017A (zh) * | 2008-01-04 | 2011-01-05 | Gw药品有限公司 | 大麻素在与抗精神病药物组合中的用途 |
| CN101977628A (zh) * | 2008-02-13 | 2011-02-16 | 塔加西普特公司 | α7烟碱激动剂和抗精神病药的组合 |
| CN102036654A (zh) * | 2008-07-24 | 2011-04-27 | 汉达医药有限责任公司 | 稳定的非典型抗精神病制剂 |
| CN103068388A (zh) * | 2010-08-09 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | Glyt1化合物与抗精神病药的组合 |
-
2017
- 2017-09-10 CN CN201710809408.7A patent/CN107469087A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1791430A (zh) * | 2003-05-16 | 2006-06-21 | 辉瑞产品公司 | 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合 |
| CN101939017A (zh) * | 2008-01-04 | 2011-01-05 | Gw药品有限公司 | 大麻素在与抗精神病药物组合中的用途 |
| CN101977628A (zh) * | 2008-02-13 | 2011-02-16 | 塔加西普特公司 | α7烟碱激动剂和抗精神病药的组合 |
| CN102036654A (zh) * | 2008-07-24 | 2011-04-27 | 汉达医药有限责任公司 | 稳定的非典型抗精神病制剂 |
| CN103068388A (zh) * | 2010-08-09 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | Glyt1化合物与抗精神病药的组合 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boachie et al. | Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa | |
| Duan et al. | Trial of chloroquines in the treatment of COVID-19 and its research progress in forensic toxicology | |
| Sabater et al. | Comparative neurocognitive effects of lithium and anticonvulsants in long-term stable bipolar patients | |
| Singla et al. | Comparison of dexmedetomidine versus midazolam for intranasal premedication in children posted for elective surgery: a double-blind, randomised study | |
| Gross et al. | Dread complications of catatonia: a case discussion and review of the literature | |
| Rukma | Glucagon for refractory anaphylaxis | |
| Lin et al. | Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia | |
| Ricke et al. | Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy | |
| CN107469087A (zh) | 用于治疗精神病的制剂 | |
| JP2025530256A (ja) | ストレス関連障害の治療のためのｍｄｍａの使用 | |
| França et al. | Botulinum toxin for the treatment of depression. | |
| Roberto et al. | Adolescent catatonia successfully treated with Lorazepam and aripiprazole | |
| Rashad et al. | The effect of different drugs on sevoflurane emergence agitation in pediatric patients undergoing hypospadias repair surgery | |
| Ayatollahi et al. | Two different concentrations of ketofol for procedural sedation and analgesia in closed reduction of nasal fracture | |
| Vora et al. | Vinpocetine: hype, hope and hurdles towards neuroprotection | |
| Centers for Disease Control and Prevention (CDC | Inadvertent use of Bicillin CR to treat syphilis infection--Los Angeles, California, 1999-2004 | |
| CN105770357A (zh) | 蒜氨酸在制备抗抑郁症药物中的用途 | |
| AU2021255701B2 (en) | Compositions and methods for treating neuropsychiatric disorders | |
| Halbert | Anti-N-methyl-D-aspartate receptor encephalitis: a case study | |
| CN104399060A (zh) | 金属硫蛋白复合制剂作为制备穴位介入治疗脑中风后遗症药物的应用 | |
| Zaidi et al. | 59 “Lithium Damaged My Spine” Might not Be a Delusion After All | |
| Robinson et al. | Laryngocardiac reflex following placement of a transesophageal electrocardiogram probe in an isoflurane-anesthetized Vietnamese Pot-Bellied pig | |
| Sablaban et al. | A man made manic: levodopa-carbidopa-induced mania in traumatic brain injury | |
| Zhan et al. | A Case of Severe Postop-erative Agitation and Literature Review | |
| Deka et al. | Electroconvulsive Therapy: Research from India |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171215 |
|
| RJ01 | Rejection of invention patent application after publication |